Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael R Sierks

Showing results (1-10 of 54) with videos related to

Pageof 6
Sort By:
Neuroscience Letters|April 28, 2009
Intracellular targeting and clearance of oligomeric alpha-synuclein alleviates toxicity in mammalian cellsBin Yuan, Michael R Sierks
The Journal of Biological Chemistry|December 30, 2020
A conformation-specific antibody against oligomeric β-amyloid restores neuronal integrity in a mouse model of Alzheimer's diseasePing He, Philip Schulz, Michael R Sierks
Biotechnology Progress|September 10, 2014
A sensitive phage-based capture ELISA for sub-femtomolar detection of protein variants directly from biological samplesStephanie Williams, Philip Schulz, Michael R Sierks
Journal of Molecular Biology|November 16, 2010
Inhibiting β-secretase activity in Alzheimer's disease cell models with single-chain antibodies specifically targeting APPShanta Boddapati, Yona Levites, Michael R Sierks
Biochemistry|May 1, 2010
Engineered proteolytic nanobodies reduce Abeta burden and ameliorate Abeta-induced cytotoxicitySrinath Kasturirangan, Shanta Boddapati, Michael R Sierks
Biochemical and Biophysical Research Communications|June 23, 2009
Cyclodextrins promote protein aggregation posing risks for therapeutic applicationsMin S Wang, Shanta Boddapati, Michael R Sierks
FEBS Letters|January 31, 2008
Anti-oligomeric single chain variable domain antibody differentially affects huntingtin and alpha-synuclein aggregatesBrent L Nannenga, Andleeb Zameer, Michael R Sierks
The European Journal of Neuroscience|September 3, 2015
Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseasesStephanie M Williams, Philip Schulz, Michael R Sierks
Biotechnology Progress|March 23, 2010
Antifibrillizing agents catalyze the formation of unstable intermediate aggregates of beta-amyloidMin S Wang, Shanta Boddapati, Michael R Sierks
Protein Engineering, Design & Selection : PEDS|September 21, 2006
Isolating recombinant antibodies against specific protein morphologies using atomic force microscopy and phage display technologiesHedieh Barkhordarian, Sharareh Emadi, Philip Schulz, et al.
Pageof 6

Showing results (1-10 of 54) with videos related to

Sort By:
Pageof 6
Neuroscience Letters|April 28, 2009
Intracellular targeting and clearance of oligomeric alpha-synuclein alleviates toxicity in mammalian cellsBin Yuan, Michael R Sierks
The Journal of Biological Chemistry|December 30, 2020
A conformation-specific antibody against oligomeric β-amyloid restores neuronal integrity in a mouse model of Alzheimer's diseasePing He, Philip Schulz, Michael R Sierks
Biotechnology Progress|September 10, 2014
A sensitive phage-based capture ELISA for sub-femtomolar detection of protein variants directly from biological samplesStephanie Williams, Philip Schulz, Michael R Sierks
Journal of Molecular Biology|November 16, 2010
Inhibiting β-secretase activity in Alzheimer's disease cell models with single-chain antibodies specifically targeting APPShanta Boddapati, Yona Levites, Michael R Sierks
Biochemistry|May 1, 2010
Engineered proteolytic nanobodies reduce Abeta burden and ameliorate Abeta-induced cytotoxicitySrinath Kasturirangan, Shanta Boddapati, Michael R Sierks
Biochemical and Biophysical Research Communications|June 23, 2009
Cyclodextrins promote protein aggregation posing risks for therapeutic applicationsMin S Wang, Shanta Boddapati, Michael R Sierks
FEBS Letters|January 31, 2008
Anti-oligomeric single chain variable domain antibody differentially affects huntingtin and alpha-synuclein aggregatesBrent L Nannenga, Andleeb Zameer, Michael R Sierks
The European Journal of Neuroscience|September 3, 2015
Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseasesStephanie M Williams, Philip Schulz, Michael R Sierks
Biotechnology Progress|March 23, 2010
Antifibrillizing agents catalyze the formation of unstable intermediate aggregates of beta-amyloidMin S Wang, Shanta Boddapati, Michael R Sierks
Protein Engineering, Design & Selection : PEDS|September 21, 2006
Isolating recombinant antibodies against specific protein morphologies using atomic force microscopy and phage display technologiesHedieh Barkhordarian, Sharareh Emadi, Philip Schulz, et al.
Pageof 6